
Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 Years
Key Takeaways
- LEADER compared 504 lecanemab-treated patients against 573 ADNI-weighted external controls, yielding a 76% lower hazard of progression to moderate/severe dementia at 36 months (HR 0.24).
- Clinical course over ~18 months showed 81.1% stable or improved and 87.5% remaining on therapy at chart extraction, with stable outcomes also seen after transition to IV or SC maintenance.
Leqembi shows lower progression rate in Alzheimer disease over 3 years, shows new data.
Lecanemab (Leqembi) was associated with a 76% lower rate of progression to moderate or severe Alzheimer disease dementia through 36 months vs an external control cohort (hazard ratio = 0.24; 95% CI = 0.15-0.39), according to real-world data from the LEADER study presented at the 19th CTAD Conference in Boston.¹
LEADER is a multicenter, retrospective study of lecanemab use in early Alzheimer disease at 13 US clinical sites, drawing on de-identified chart and electronic medical record data plus health care professional surveys and interviews. The analysis included 560 patients who had received at least 7 initiation infusions as of September 2026. The prespecified comparison pitted LEADER patients (n = 504) against an Alzheimer’s Disease Neuroimaging Initiative–weighted external control cohort (n = 573). A separate post hoc, exploratory meta-analysis pooled 16 published cohorts (approximately 5000 patients) from 6 countries, treated for at least 6 months between 2023 and 2026.¹
Among 546 patients assessable after an average of about 18 months, 81.1% were stable (75.8%) or improved (5.3%) vs baseline, and 87.5% remained on treatment at chart extraction. Of 43 patients with baseline and follow-up amyloid positron emission tomography scans, 33 (77%) became amyloid negative at a median of 18.1 months. After 18 months, 218 patients moved to IV maintenance every 4 weeks and 64 to once-weekly subcutaneous maintenance; 71.1% and 76.6%, respectively, remained stable. Amyloid-related imaging abnormalities (ARIA) with edema or effusion (ARIA-E) occurred in 6.6% of LEADER patients vs 6.3% in the ALZ-NET registry, and those with hemosiderin deposition (ARIA-H) in 11.1% vs 10.1%. In the meta-analysis, pooled ARIA-E was 4.0% vs 12.6% in Clarity AD, ARIA-H 9.4% vs 17.3%, symptomatic ARIA 0.8% vs 2.8%, and discontinuation due to adverse events 3.2%.2
Persistence of 87.5% reflects status at chart extraction, after about 19 months.¹ Retrospective chart data without a placebo arm are vulnerable to selection bias, incomplete documentation, and confounding, and the release does not define “stable,” describe the weighting method, or report APOE ε4–specific figures, stating only that ARIA rates were generally consistent regardless of ε4 status. The amyloid imaging subgroup was small, and the cross-study ARIA comparisons involve different populations and monitoring conditions. The signal is most relevant to patients with early symptomatic disease already on therapy, and durability of benefit beyond 36 months remains unproven.¹
Lecanemab is a humanized IgG1 monoclonal antibody that targets aggregated soluble (protofibril) and insoluble forms of amyloid-beta.¹ It is approved in 53 countries and regions, with 18 months of biweekly IV initiation followed by IV maintenance every 4 weeks (approved in 9 countries) or subcutaneous maintenance at 360 mg (Leqembi Iqlik), approved in the US in August 2025. Subcutaneous initiation at 500 mg was approved in the US in July 2026 and in China and Japan in September 2026.¹
Brent Berry, MD, PhD, of Minneapolis Clinic of Neurology said continued treatment may help keep patients in early stages of Alzheimer disease longer.¹ IV maintenance applications are filed in 11 additional countries, and subcutaneous initiation is under review in 4. Ongoing studies include AHEAD 3-45 in preclinical Alzheimer disease (since July 2020) and Tau NexGen in dominantly inherited Alzheimer disease (since January 2022).¹
References
1. New 3-year real-world LEQEMBI data presented at CTAD 2026. Press release. November 18, 2026. Accessed November 19, 2026.
2. van Dyck CH, Swanson CJ, Aisen P, et al.
Related to this article








